GSK reports strong results and says it is ‘well positioned’ when it comes to pharma tariffs

Takeaways from the Key Takeaways

• U.S.-listed shares of GSK are gaining in intraday trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry. 
• The company affirmed that it will achieve its full-year target of 3% to 5 percent growth in turnover and 6% to 8 percent growth in core earnings per shares at constant exchange rates.
• GSK shares listed in the U.S., which had risen 15% this year by Wednesday, climbed another 3% before market opening. 

The U.S. listed shares of GSK (GSK), a British pharma giant, are up in intraday trading on Wednesday after it posted better than expected first-quarter results. It also said that it was “well-positioned” if the Trump administration imposed tariffs against the pharma industry. 

The London-based firm posted core earnings per shares of 39.7 pence ($0.53). This is well above VisibleAlpha’s consensus of 31.5 pence. Turnover rose 4% year–over-year at constant exchange rates to 7.52 billion pounds ($10.04 billion), also above projections.

The company confirmed its full-year guidance. This included a turnover growth of between 3% and 5%, and a core EPS increase of between 6% and 8% at constant rates of exchange.

GSK stated that it was “well positioned” to respond to potential financial impacts of sector-specific duties, should they be implemented. Mitigation options have been identified in supply chain and productivity programs.

The U.S. listed shares of GSK are up 3%. They entered Wednesday with a 15% gain for the year.

UPDATE—April 30, 2025: This article has been updated to include refreshed share prices.